Study guide

9.3 Snake and Spider Envenomations & Heavy Metal Chelation

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

9.3 Snake and Spider Envenomations & Heavy Metal Chelation

Key Takeaways Explain This Topic AI

Crotalinae (pit viper) bites cause tissue destruction and venom-induced consumptive coagulopathy; Crotalidae Polyvalent Immune Fab (CroFab, 4-6 vials IV) requires maintenance dosing (2 vials q6h x 3 doses) due to its shorter half-life and risk of late recurrent coagulopathy, whereas Crotalidae Immune F(ab')2 (Anavip, 10 vials IV) provides a prolonged half-life that eliminates maintenance dosing and reduces late recurrent thrombocytopenia.

Coral snake envenomation induces neurotoxic respiratory arrest through post-synaptic acetylcholine receptor blockade with minimal early local signs, requiring early empiric antivenin and proactive mechanical ventilation.

Black widow bites inject alpha-latrotoxin, triggering massive calcium influx, muscle spasms, and severe abdominal rigidity treated with intravenous opioids and benzodiazepines, reserving equine antivenin for refractory cases; brown recluse bites cause sphingomyelinase D-mediated dermonecrosis requiring supportive wound care and strict avoidance of acute surgical debridement.

Severe lead encephalopathy (blood lead level >=70 mcg/dL) mandates sequential chelation with intramuscular Dimercaprol (BAL) administered at least 4 hours before intravenous Calcium Disodium EDTA (CaNa2EDTA) to prevent toxic lead redistribution into the central nervous system; oral Succimer (DMSA) is reserved for blood lead levels 45 to 69 mcg/dL.

Acute iron poisoning produces corrosive gastrointestinal injury, uncoupled oxidative phosphorylation, and high anion gap metabolic acidosis; intravenous deferoxamine is infused at 15 mg/kg/h, forming excreted ferrioxamine ('vin rosé' urine), with therapy discontinued when shock resolves, acidosis clears, and serum iron falls below 350 mcg/dL.

Last updated: October 2026

9.3 Snake and Spider Envenomations & Heavy Metal Chelation

Note

Independent BCEMP study resource provided by ExamFinch. Content covers emergency toxicology, specialized antidotes, and clinical pharmacotherapy principles.

Envenomations and heavy metal intoxications represent complex clinical toxicology emergencies requiring targeted biologic and chelating countermeasures. Envenomations by North American pit vipers, coral snakes, and spiders provoke multi-organ toxicities ranging from venom-induced consumptive coagulopathy (VICC) and tissue necrosis to flaccid neuroparalysis and agonizing autonomic cramping. Concurrently, heavy metal poisonings—such as lead and iron—disrupt essential cellular enzymes and mitochondrial energy production, demanding rigorous adherence to chelator administration sequencing and endpoints.

Crotalinae (Pit Viper) Envenomation & Antivenom Pharmacotherapy

Subfamily Crotalinae (pit vipers) accounts for approximately 95% of native venomous snakebites in the United States, comprising rattlesnakes ( Crotalus ), copperheads ( Agkistrodon contortrix ), and cottonmouths/water moccasins ( Agkistrodon piscivorus ). Pit vipers possess heat-sensing facial pits, retractable front fangs, and triangular heads.

Venom Pathophysiology

Crotalid venom is a sophisticated proteomic mixture of enzymes and non-enzymatic proteins:

Metalloproteinases & Hyaluronidase : Degrade vascular basement membranes, extracellular matrix, and collagen, producing intense local tissue necrosis, ecchymosis, bleb formation, and extreme capillary leak.

Phospholipase A 2 \text{A}_2 A 2 ​ : Induces myonecrosis, cellular lysis, and systemic platelet destruction.

Thrombin-like Glycoproteins (e.g., Crotalase) : Directly cleave fibrinogen into friable, abnormal fibrin monomers that lack cross-linking, precipitating Venom-Induced Consumptive Coagulopathy (VICC) characterized by severe hypofibrinogenemia , markedly elevated PT/INR, and profound thrombocytopenia .

Systemic Manifestations : Hypotension, shock, metallic or minty taste, perioral paresthesias, nausea, vomiting, and diffuse fasciculations.

Antivenom Pharmacotherapy: CroFab vs. Anavip

Definitive treatment for moderate-to-severe Crotaline envenomation is immediate antivenom therapy. Two FDA-approved formulations are available in the United States:

Loading diagram...

1. Crotalidae Polyvalent Immune Fab (CroFab, Ovine)

Structure : Monovalent Fab immunoglobulin fragments (~46 kDa) derived from sheep immunized with venom from four North American pit vipers ( Crotalus atrox, C. adamanteus, C. scutulatus , and Agkistrodon piscivorus ).

Initial Loading Dose : 4 to 6 vials IV reconstituted in 250 mL of 0.9% NaCl and infused over 60 minutes (initiate slowly at 25 to 50 mL/h for the first 10 minutes to observe for acute hypersensitivity reactions, then increase to complete within 1 hour).

Establishing Initial Control : Defined as halting the progression of swelling, normalization of vital signs, and stabilization/reversal of coagulopathy (platelets > 100 , 000 / μ L >100,000/\mu\text{L} > 100 , 000/ μ L , fibrinogen > 100 mg/dL >100\text{ mg/dL} > 100 mg/dL , normal PT/INR). If initial control is not achieved after the first dose, administer an additional 4 to 6 vials and repeat until control is established.

Mandatory Maintenance Regimen : Once initial control is secured, administer 2 vials IV every 6 hours for 3 doses (at hours 6, 12, and 18).

Pharmacokinetic Limitation & Recurrent Coagulopathy : CroFab has a short terminal elimination half-life (~12 to 15 hours). Because venom components have a larger molecular weight and depot slowly from tissue over days, the antivenom clears faster than circulating venom. Consequently, up to 30% to 50% of patients experience delayed recurrent coagulopathy or recurrent thrombocytopenia 2 to 7 days post-discharge. Outpatient follow-up with CBC and PT/INR at 48 to 72 hours and 5 to 7 days is mandatory.

2. Crotalidae Immune F(ab’) 2 \text{F(ab')}_2 F(ab’) 2 ​ (Anavip, Equine)

Structure : Bivalent F(ab’) 2 \text{F(ab')}_2 F(ab’) 2 ​ immunoglobulin fragments (~100 kDa) derived from horses immunized with venom from Bothrops asper and Crotalus durissus .

Initial Loading Dose : 10 vials IV infused over 60 minutes . Re-evaluate at 1 hour; if initial control is not achieved, administer another 10 vials .

Key Pharmacokinetic Advantage : The larger bivalent F(ab’) 2 \text{F(ab')}_2 F(ab’) 2 ​ molecule has a significantly prolonged terminal elimination half-life ( ~5.5 days [133 hours] , compared to ~15 hours for CroFab). Because therapeutic antivenom concentrations persist in the circulation throughout the entire window of tissue venom redistribution, NO scheduled maintenance infusions are required . Anavip dramatically reduces the incidence of late recurrent coagulopathy and recurrent thrombocytopenia.

Coral Snake Envenomation

Eastern ( Micrurus fulvius ) and Texas ( Micrurus tener ) coral snakes belong to the family Elapidae (related to cobras and mambas). They are recognized by the classic ring pattern: "Red on yellow, kill a fellow; red on black, friend of Jack."

Clinical Presentation & Management

Neurotoxic Mechanism : Unlike pit vipers, coral snake venom contains potent, non-cytotoxic post-synaptic alpha-neurotoxins that bind competitively to nicotinic acetylcholine receptors at the neuromuscular junction, blocking neuromuscular transmission.

Minimal Local Findings : The bite site typically exhibits little to no pain, zero swelling, and no tissue necrosis, often leading patients and clinicians to underestimate severity.

Delayed Life-Threatening Paralysis : Neurotoxic symptoms are classically delayed by 12 to 18 hours post-bite. Once clinical weakness begins, rapid deterioration ensues: ptosis, diplopia, bulbar palsies (dysphagia, dysarthria), descending symmetric flaccid paralysis, and fatal diaphragmatic respiratory failure .

Pharmacotherapy : Administer equine North American Coral Snake Antivenin ( Micrurus fulvius ) empirically (typically 3 to 5 vials IV infused over 1 hour) for any patient with a confirmed native coral snake bite, BEFORE the onset of neurotoxic symptoms . Once respiratory muscle paralysis has developed, antivenom does not rapidly reverse established receptor blockade; patients require prolonged endotracheal intubation and mechanical ventilation until new receptors are synthesized.

Spider Envenomations: Black Widow vs. Brown Recluse

Clinical Parameter Black Widow ( Latrodectus mactans ) Brown Recluse ( Loxosceles reclusa )

Identification Shiny black body with ventral red hourglass marking Light-to-medium brown body with dark violin/fiddle marking on dorsal cephalothorax

Primary Venom Toxin Alpha-latrotoxin Sphingomyelinase D

Mechanism of Action Binds presynaptic neurexins/CIRL, forming pore channels that cause massive, uncontrolled calcium influx and vesicular release of acetylcholine and norepinephrine Cleaves cell membrane sphingomyelin, activates complement cascades, triggers intense neutrophil chemotaxis and microvascular dermal thrombosis

Local Lesion Mild local pain, faint targetoid erythematous bite with central puncta; no tissue necrosis Sinking necrotic lesion: central violaceous bleb surrounded by pale ischemic ring and outer erythema ( "Red, White, and Blue" sign )

Systemic Manifestations Agonizing, spreading muscle cramps, rigid "board-like" abdominal wall without peritoneal tenderness, diaphoresis, hypertension, tachycardia, facies latrodectismica Mostly local; rare systemic loxoscelism (massive intravascular hemolysis, DIC, hemoglobinuria, acute tubular necrosis, shock; seen primarily in children)

Emergency Management Supportive Pharmacotherapy : IV opioids (fentanyl, morphine) for pain + IV benzodiazepines (lorazepam, diazepam) for muscle rigidity. Antivenin reserved for refractory crisis Supportive Wound Care : Cold compresses, elevation, tetanus prophylaxis. Surgical excision is strictly contraindicated in acute phase (delays healing and worsens scarring)

Warning

Equine Black Widow Antivenin Safety : Equine Latrodectus mactans antivenin carries an exceptionally high risk of immediate anaphylaxis and delayed serum sickness. It is strictly reserved for life-threatening latrodectism refractory to high-dose opioids and benzodiazepines (e.g., severe uncontrollable hypertension, impending myocardial infarction, or pregnant patients with intractable uterine spasms).

Heavy Metal Toxicity & Chelation Pharmacotherapy

Heavy metals bind cellular functional groups (especially sulfhydryl, amino, and carboxyl groups), inactivating critical metabolic enzymes and generating oxidative free radicals.

1. Lead Poisoning & Encephalopathy

Lead accumulates in erythrocytes, soft tissues (brain, kidney), and bone (95% of total body burden in adults). It inhibits heme biosynthesis enzymes—specifically δ \delta δ -aminolevulinic acid dehydratase (ALAD) and ferrochelatase—producing microcytic sideroblastic anemia and classic basophilic stippling on peripheral blood smear. Chronic toxicity causes lead colic (severe cramping abdominal pain), motor peripheral neuropathy (bilateral wrist drop, foot drop), nephropathy, and cognitive impairment. Acute severe toxicity provokes lead encephalopathy (cerebral edema, seizures, coma, death).

Chelation Protocols Based on Whole Blood Lead Levels (BLL)

Whole blood lead concentrations determine therapy:

BLL 45 to 69 mcg/dL (Asymptomatic or Mild Symptoms) :

Succimer (DMSA, Dimercaptosuccinic Acid) : Oral water-soluble analog of dimercaprol.

Dosing : 10 mg/kg PO every 8 hours for 5 days , followed by 10 mg/kg PO every 12 hours for 14 days (total 19-day course). Recheck BLL 2 weeks post-therapy.

Adverse Effects : Gastrointestinal distress, transient elevation in hepatic transaminases, neutropenia, and prominent sulfuric breath/urine odor.

BLL ≥ 70 mcg/dL \ge 70\text{ mcg/dL} ≥ 70 mcg/dL or Acute Lead Encephalopathy (Medical Emergency) :

Requires dual parenteral chelation with Dimercaprol (BAL, British Anti-Lewisite) and Calcium Disodium EDTA ( CaNa 2 EDTA \text{CaNa}_2\text{EDTA} CaNa 2 ​ EDTA ) .

Dimercaprol (BAL) : Dosed at 75 mg/ m 2 \text{m}^2 m 2 (or 4 mg/kg) deep IM every 4 hours . It is lipophilic, crosses the blood-brain barrier, and chelates intracellular lead. Formulated in peanut oil (strictly contraindicated in severe peanut allergy!).

Calcium Disodium EDTA ( CaNa 2 EDTA \text{CaNa}_2\text{EDTA} CaNa 2 ​ EDTA ) : Dosed at 1,000 to 1,500 mg/ m 2 \text{m}^2 m 2 /day IV continuous infusion (or divided q8–12h). Chelates extracellular and bone lead, which is excreted renally. CRITICAL DRUG SEQUENCING IN ACUTE LEAD ENCEPHALOPATHY

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ STEP 1: Administer DIMERCAPROL (BAL) 75 mg/m2 Deep IM First │
  • │ ▼ │
  • │ WAIT AT LEAST 4 HOURS BEFORE PROCEEDING │
  • │ ▼ │
  • │ STEP 2: Initiate CALCIUM DISODIUM EDTA (CaNa2EDTA) IV Continuous Infusion │
  • │ │
  • │ RATIONALE: Giving EDTA alone mobilizes lead from bone stores and redistributes│
  • │ toxic lead into the brain, acutely worsening encephalopathy and death! │
  • │ NEVER USE DISODIUM EDTA (Na2EDTA): Chelates serum calcium -> Fatal Arrest! │
  • └─────────────────────────────────────────────────────────────────────────────┘

Caution

Fatal Error Warning: Disodium EDTA vs. Calcium Disodium EDTA Ensure the medication ordered is Calcium Disodium EDTA ( CaNa 2 EDTA \text{CaNa}_2\text{EDTA} CaNa 2 ​ EDTA ) . Inadvertent administration of Disodium EDTA ( Na 2 EDTA \text{Na}_2\text{EDTA} Na 2 ​ EDTA ) binds ionized calcium, precipitating acute, catastrophic hypocalcemia, tetany, intractable ventricular dysrhythmias, and fatal cardiac arrest. Disodium EDTA is never used for lead chelation.

2. Acute Iron Toxicity: Corrosive Necrosis & Deferoxamine

Iron is directly corrosive to the gastrointestinal mucosa. Once circulating transferrin is fully saturated, non-transferrin-bound "free iron" catalytically generates highly reactive hydroxyl free radicals via the Fenton reaction, inducing lipid peroxidation, capillary leak, uncoupling of oxidative phosphorylation, and acute hepatocellular necrosis.

The Five Clinical Stages of Iron Toxicity

Stage 1 (0.5 to 6 hours post-ingestion) : Corrosive gastrointestinal stage: severe vomiting, hematemesis, bloody diarrhea, abdominal pain. Absence of GI symptoms in the first 6 hours reliably excludes serious toxicity.

Stage 2 (6 to 24 hours) : Apparent "latent" or quiescent phase: gastrointestinal symptoms subside as iron clears from the gut into cells, but severe cellular toxicity quietly smolders.

Stage 3 (12 to 48 hours) : Shock and metabolic stage: high anion gap metabolic acidosis, distributive and cardiogenic shock, cyanosis, and acute tubular necrosis.

Stage 4 (2 to 5 days) : Hepatotoxicity stage: acute hepatic failure, hyperbilirubinemia, profound coagulopathy, and hypoglycemia.

Stage 5 (2 to 6 weeks) : Delayed scarring stage: gastric outlet obstruction and pyloric strictures from cicatricial healing.

Diagnostic Iron Levels & Deferoxamine Protocol

Peak Serum Iron : Draw serum iron concentration 4 to 6 hours post-ingestion :

Peak iron < 350 μ g/dL <350\ \mu\text{g/dL} < 350 μ g/dL : Low risk of systemic toxicity; supportive care.

Peak iron 350 to 500 μ g/dL 350\text{ to }500\ \mu\text{g/dL} 350 to 500 μ g/dL : Mild to moderate toxicity; observe, consider chelation if symptomatic.

Peak iron > 500 μ g/dL >500\ \mu\text{g/dL} > 500 μ g/dL : Severe toxicity; mandatory parenteral chelation.

Peak iron > 1 , 000 μ g/dL >1,000\ \mu\text{g/dL} > 1 , 000 μ g/dL : Life-threatening, catastrophic intoxication.

Antidote : Deferoxamine Mesylate (Desferal) :

Mechanism : A microbial hexadentate siderophore that selectively binds free ferric iron ( Fe 3 + \text{Fe}^{3+} Fe 3 + ) with extreme affinity ( K a = 10 31 K_a = 10^{31} K a ​ = 1 0 31 ), forming ferrioxamine , a water-soluble, non-toxic complex eliminated in the urine.

Dosing : Administer as a continuous intravenous infusion at 15 mg/kg/h (the label maximum is 15 mg/kg/h and 6 g per 24 hours; start lower if hypotensive and titrate up, and higher rates are used only under toxicologist guidance). Avoid rapid boluses, which trigger severe histamine release, flushing, and vascular collapse.

Vin Rosé Urine : As ferrioxamine is excreted in the urine, it imparts a classic reddish-orange "vin rosé" appearance. The presence of vin rosé urine confirms iron chelation, but its absence does not rule out toxicity.

Definitive Treatment Endpoints : Discontinue deferoxamine when:

The patient is clinically asymptomatic and hemodynamically stable.

The high-anion-gap metabolic acidosis has completely resolved.

Serum iron concentration decreases to < 350 μ g/dL <350\ \mu\text{g/dL} < 350 μ g/dL .

The urine clears of vin rosé coloration (returns to normal amber color).

Prolonged Infusion Risk : Infusions lasting > 24 to 48 hours >24\text{ to }48\text{ hours} > 24 to 48 hours elevate the risk of Deferoxamine-induced Acute Respiratory Distress Syndrome (ARDS) and opportunistic infections with Yersinia enterocolitica (which utilizes ferrioxamine as a growth-promoting siderophore).

Heavy Metal Chelators and Snake Antivenom Reference Matrix

Toxic Entity Pathophysiologic Target Clinical Trigger / Severity First-Line Antidote / Chelator Dosing & Route of Administration Critical Clinical Pearls & Warnings

Crotalinae (Pit Viper) Metalloproteinases & thrombin-like glycoproteins Progressive swelling, severe thrombocytopenia, hypofibrinogenemia CroFab (Ovine Fab) or Anavip (Equine F(ab’) 2 \text{F(ab')}_2 F(ab’) 2 ​ ) CroFab: 4–6 vials IV, then 2 vials q6h x 3; Anavip: 10 vials IV initially CroFab carries 30–50% recurrent coagulopathy risk; Anavip eliminates maintenance due to 5.5-day half-life.

Coral Snake Post-synaptic alpha-neurotoxins Any confirmed bite by native Eastern/Texas coral snake Micrurus fulvius Antivenin (Equine) 3 to 5 vials IV infused over 1 hour Administer empirically BEFORE onset of symptoms; antivenom does not rapidly reverse established paralysis.

Severe Lead Toxicity Sulfhydryl enzyme inhibition, heme synthesis block Blood lead ≥ 70 μ g/dL \ge 70\ \mu\text{g/dL} ≥ 70 μ g/dL or acute lead encephalopathy Dimercaprol (BAL) + Calcium Disodium EDTA BAL: 75 mg/ m 2 \text{m}^2 m 2 deep IM q4h; EDTA: 1,000–1,500 mg/ m 2 \text{m}^2 m 2 /day IV infusion Administer BAL at least 4 hours BEFORE EDTA to prevent brain redistribution; never use Disodium EDTA.

Moderate Lead Poisoning ALAD & ferrochelatase enzyme inhibition Blood lead 45 to 69 mcg/dL in outpatients Succimer (DMSA) 10 mg/kg PO TID x 5 days, then BID x 14 days (19 days total) Water-soluble oral chelator; causes sulfuric breath odor and transient transaminitis; monitor CBC.

Acute Iron Overdose Direct mucosal corrosion & free radical lipid peroxidation Serum iron > 500 μ g/dL >500\ \mu\text{g/dL} > 500 μ g/dL at 4–6h; shock; metabolic acidosis Deferoxamine Mesylate (Desferal) 15 mg/kg/h continuous IV infusion Imparts "vin rosé" urine; stop when acidosis clears and iron < 350 μ g/dL <350\ \mu\text{g/dL} < 350 μ g/dL ; risk of ARDS if > 24 – 48 h >24\text{--}48\text{h} > 24 – 48 h .